Philosophy of AR >
Animal Testing Index >
November 13, 2005
Technology far ahead of blunt vivisection
DNA Print Pharmaceuticals to Combine Computer Modeling With Genetics to
Improve Drug Development
SARASOTA, FL -- (MARKET WIRE) -- 11/08/2005 -- DNAPrintT genomics, Inc. (OTC
BB: DNAG) today announced that DNAPrint Pharmaceuticals, Inc.'s
Computational Biology Division, which was recently acquired from Kenna
Technologies, Inc., is preparing to launch its services contract business
for the pharmaceutical and biotechnology industries.
By incorporating DNAPrint's pharmacogenomics contract services with those of
the Computational Biology Division, the end result will be a unique solution
for optimizing clinical trials. DNAPrint will demonstrate to drug developers
that they can learn more about a new drug's patient benefit as well as an
optimum dosing regimen.
The computational biology scientists at DNAPrint Pharmaceuticals have
developed a system for analyzing complex biological processes. "Our offering
is pragmatic," says Dr. Barbara Handelin, General Manager of Computational
Biology. "Even with an imperfect understanding of disease and human
physiology, we have shown that we can create highly predictive models that
improve the understanding of researchers. We are especially excited to
demonstrate to potential clients how modeling can work synergistically with
genetic studies of drug response."
DNAPrint genomics utilizes a proprietary technology that measures variations
among patient populations that relate to their responses to drugs. The
combination of the two technologies will assist developers of pharmaceutical
products in identifying important patient factors that impact how a specific
drug will affect different groups of patients. Some of these factors are
inborn, such as genetic markers; others are identified by the Company's
computer simulations, which will be inherent to the role of the drug in the
disease under treatment. The Company will also help identify genetic and
other patient factors predisposing patients to toxic side effects.
DNAPrint also uses simulations to model the molecular and cellular effects
of a drug candidate so that researchers can ask many more "what if"
questions about dose levels and scheduling as opposed to actual human or
animal studies. These simulations then guide the design of actual clinical
trials with advanced "intelligence" about the likely outcomes. The
likelihood of successful trials, targeted to the right patients with an
effective dosing regimen is greatly enhanced; and could lead to reduced time
and costs of clinical studies.
"We invite everyone to use our services," said Hector J. Gomez, M.D., Ph.D.,
DNAPrint's Chairman and Chief Medical Officer. "We believe that bringing
computer modeling and genetics together is a natural fit for optimizing drug
discovery and development. These are independent approaches that together
start to improve preclinical and clinical development from strictly
empirical medicinal chemistry trials to mechanistically driven human biology
"Simply put, DNAPrint will utilize computational modeling to develop drugs
more efficiently," said DNAPrint President and Chief Executive Officer
Richard Gabriel. "It will play a valuable role in any company's efforts to
pursue the development of drugs which maximize efficacy and minimize side
effects by tailoring medications for specific individuals and well-defined
DNAPrintT genomics, Inc. (www.dnaprint.com) is a developer of genomics-based
products and services focused on drug development, pharmacogenomic
diagnostic tests, forensics technology and consumer genetic tests. DNAPrint
Pharmaceuticals, Inc., a wholly owned subsidiary, is responsible for the
development of diagnostic tests and theranostic products (drug/test
combination) and also provides Computational Biology and Pharmacogenomics
Services. The Company's first theranostic product is PT-401, a "Super EPO"
(erythropoietin) dimer protein drug for treatment of anemia in renal
dialysis patients (end stage renal disease). Currently in pre-clinical
development, PT-401 will be targeted to patients with a genetic profile
indicating their propensity to have the best clinical response. DNAPrint's
family of products for the law enforcement forensics and consumer markets
include DNAWITNESST, RETINOMET, ANCESTRYbyDNAT and EURO-DNAT.
All statements in this press release that are not historical are
forward-looking statements. Such statements are subject to risks and
uncertainties that could cause actual results to differ materially from
those projected, including, but not limited to, uncertainties relating to
technologies, product development, manufacturing, market acceptance, cost
and pricing of DNAPrint's products, dependence on collaborations and
partners, regulatory approvals, competition, intellectual property of
others, and patent protection and litigation. DNAPrint genomics, Inc.
expressly disclaims any obligation or undertaking to release publicly any
updates or revisions to any forward-looking statements contained herein to
reflect any change in DNAPrint's expectations with regard thereto or any
change in events, conditions, or circumstances on which any such statements
CEO and President
The Wall Street Group, Inc.
SOURCE: DNAprint Genomics, Inc.
Animal experiments have:
a 63% failure rate when detecting human carcinogens
a 75-95% failure rate for detecting drug side effects
a 70% failure rate for detecting drugs which cause birth defects
Success rates lower than those achieved by uneducated guesswork.
This is not science!!
See more at
(unreliability of vivisection)
Vivisection Information Network (VIN)
Providing the evidence for abolition
MAIL TO THIS ADDRESS WILL BE DELETED. Instead send all mail to